The Alpha Fetoprotein (AFP) Tumor Marker Test measures AFP levels in blood to help detect and monitor cancers such as liver cancer, testicular cancer, and certain ovarian tumors. Elevated AFP may also be seen with liver disease, cirrhosis, or hepatitis. Doctors order this test for patients at risk of or being treated for cancer. Results provide essential insight for diagnosis, monitoring treatment response, and tracking cancer recurrence or progression.

The CA 125 Test measures the level of cancer antigen 125 in blood, a protein often elevated in ovarian cancer and some other conditions. While not used alone for diagnosis, it helps monitor treatment effectiveness, detect recurrence, or assess disease progression. Elevated CA 125 may also be seen in endometriosis, fibroids, or pelvic inflammation. Doctors use this test to support cancer management and track overall reproductive and abdominal health.

The Cancer Screening - Women Panel is a comprehensive set of blood tests designed to detect various cancer markers in women. This panel assesses levels of specific proteins that can be elevated in the presence of certain types of cancer. By measuring these markers, healthcare providers can gain valuable insights into a patient's risk of having cancer, monitor the progression of the disease, and evaluate the effectiveness of treatment.

The Tumor Necrosis Factor-Alpha (TNF-α) Test measures levels of this cytokine, a key marker of inflammation and immune system activity. Elevated TNF-α may indicate autoimmune disease, chronic inflammation, sepsis, or certain cancers. Doctors order this test for patients with rheumatoid arthritis, Crohn’s disease, or persistent fever. Results provide critical insight into immune dysregulation, disease progression, and response to anti-inflammatory therapies.

 The CA-1 Cancer Screening - Women panel is specifically designed as an initial screening tool for the early detection of various cancers that commonly affect women. This panel combines several tumor markers and protein measurements, each carefully selected for their relevance in detecting specific cancer types. The panel is an important resource for those who are at increased risk of cancer, either due to family history, genetic predisposition, or other risk factors. By measuring specific biomarkers, this panel helps in identifying cancer at an early stage, where treatment can be more effective and less invasive.

 The CA-2 Cancer Screening - Women panel is a specialized diagnostic tool designed for the early detection and ongoing monitoring of various cancers specifically in women. It expands upon basic cancer screening by including additional markers that provide a wider range of detection and insight into different types of cancers. This panel is particularly valuable for women who are at increased risk due to genetic predispositions, family history, or environmental factors. It helps in the early identification of cancer, potentially improving the effectiveness of treatments and increasing the chances of successful outcomes.